-
Mashup Score: 0
May 7, 2024 — RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced that the Food and Drug Administration (FDA) has granted 510(k) clearance for its AngioFlow by RapidAI solution. The module delivers perfusion imaging analysis directly within the interventional suite to promote greater clinical confidence, workflow efficiency, and potentially improve patient outcomes. “We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke pati
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 4Documentary Led by HonorHealth Research Institute Focuses on Injuries to Doctors and Nurses Working in Cardiology - 11 hour(s) ago
May 7, 2024 — HonorHealth Research Institute’s David G. Rizik, M.D., narrates and is a co-producer of a documentary focused on radiation and orthopedic injuries suffered by doctors and nurses who work in cardiac catheterization laboratories where they apply the very latest non-surgical technologies to treat the world’s leading cause of death, heart disease. The premier of a two-hour, six-part version of Scattered Denial: The Occupational Dangers of Radiation will stream beginning Sunday, April 28, on www.ScatteredDenial.org, preceding a one-hour version that will air nationally in July on PBS. “The ‘scatter’ is radiation scatter, and ‘denial’ is how we’ve denied that this was happening until it was too late,” said Dr. Rizik, research director of the Cardiovascular Research Division at HonorHealth Research Institute, the world’s leader in studies tracing the dangers of occupational radiation exposure among medical professionals, and how they can be protected by a new class of radiation
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Medtronic TAVR Outcomes from SMART Trial and Optimize PRO Addendum on Evolut TAVR Presented at SCAI 2024 Scientific Sessions - 11 hour(s) ago
May 7, 2024 — Medtronic announced the release of important clinical outcomes in two leading transcatheter valve therapies from studies presented at the recent Society for Cardiovascular Angiography & Interventions 2024 Scientific Sessions, SCAI 2024, held May 2-4 in Long Beach, CA. Medtronic transcatheter therapies showed excellent outcomes in the treatment of congenital heart disease and severe aortic stenosis, as reported in a written statement released by the company and summarized below. “The data presented at SCAI 2024 reinforces our commitment to providing solutions for structural heart patients with varying and complex anatomies,” said Nina Goodheart, senior vice president and president, Structural Heart & Aortic, which is part of the Cardiovascular Portfolio at Medtronic. Goodheart added, “We are seeing positive outcomes for patient groups in need of minimally invasive solutions – including meaningful insights into the benefits of the Harmony TPV system and additional evidence
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
May 7, 2024 — A new study by a global team of researchers, led by Sook-Lei Liew, PhD, of USC’s Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), has revealed that areas of age-related damage in the brain relate to motor outcomes after a stroke—a phenomenon that may be under-recognized in stroke research. The study was published online on May 3, 2024, in Neurology, the medical journal of the American Academy of Neurology. A stroke often leads to motor impairment, which is traditionally linked to the extent of damage to the corticospinal tract (CST), a crucial brain pathway for motor control. Signaling along the CST is involved in a variety of movements, including walking, reaching, and fine finger movements like writing and typing. However, stroke recovery outcomes aren’t fully predicted by damage to the CST, suggesting other factors are at play. The new observational study from the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) Stroke Recovery
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Women and Black Patients Less Likely to Receive Catheter-based Treatment for Pulmonary Embolism According to REAL-PE Analysis Presented at SCAI 2024 - 11 hour(s) ago
May 7, 2024 — Women and black patients were less frequently treated with minimally invasive therapy compared to men or non-Black patients, according to new data from the REAL-PE analysis which investigated catheter-based pulmonary embolism (PE) treatment. The late-breaking results were presented in a session, “Disparities in Pulmonary Embolism Care: Insights from Big Data Analytics” during the recently-held Society for Cardiovascular Angiography & Interventions SCAI 2024 Scientific Sessions. A snapshot summary of the outcomes, as presented in a written statement issued by SCAI, follows. Study Summary REAL-PE analyzed data from patients within the Truveta database diagnosed with PE and treated with USCDT or MT for PE. Patient characteristics including race, ethnicity, age, sex, comorbidities, and prior diagnoses were assessed to investigate their association with the type of treatment used. Of the more than 430,000 patients diagnosed with PE, about 2,000 patients analyzed were treated w
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
May 6, 2024 — SMT (Sahajanand Medical Technologies), a leading medical device company at the forefront of innovative patient care in the cardiovascular segment has announced a strategic partnership with HeartX, a pioneering MedTech company focused on research and development. Through this collaboration, SMT gains an innovative product line in the Congenital Heart Defect space. This collaboration not only broadens SMT’s advanced product offerings within the Congenital Heart Defect space but also marks a significant stride toward revolutionizing healthcare on a global scale. HeartX’s portfolio includes advanced products like the JOVE VB Stent for Sinus Venous ASD, JOVE Versatile ASD (VASO), Fenestrated VASO and JOVE PFO, with ongoing developments in PDA and VSD closures as well as advanced visualization systems for structural interventions. The collaboration between SMT and HeartX aims to address gaps in current medical procedures by prioritizing simplicity, efficiency, and cost reductio
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Teleflex Announces the Limited Market Release of the Wattson Temporary Pacing Guidewire - 2 day(s) ago
May 6, 2024 — Teleflex Incorporate, a leading global provider of medical technologies, today announced that the Wattson Temporary Pacing Guidewire limited market release has commenced at Columbia University Irving Medical Center. The first cases were performed by Dr. Tamim Nazif, Director of Clinical Research, Dr. Susheel Kodali, Professor of Medicine and Director of the Structural Heart and Valve Center, and Dr. Isaac George, Surgical Director of the Heart Valve Center. Featuring a simple design to create procedural efficiencies, the Wattson Temporary Pacing Guidewire offers dual functionality, supporting both valve delivery and ventricular bipolar pacing during structural heart procedures, including transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV). The device offers a procedural alternative designed to avoid potential complications1, steps1, and costs2 associated with traditional right ventricular pacing. From its flexible distal pigtail shape to i
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent covering the use of TNX-103 (oral levosimendan), TNX-102 (subcutaneous levosimendan), TNX-101 (IV levosimendan), the active metabolites of levosimendan (OR1896 and OR18955) and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients, entitled: “LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF).” “Expanding our intellectual property estate for levosimendan is a strategic priority for Tenax. We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano, President & Chief
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0DAIC's Top 10 for April - 2 day(s) ago
Clinical trials and innovative technology took center stage during the month of April, racking up some record number views. Here is a look at what DAIC viewers were reading last month: 1. New Study Reveals 65 and Older Population Lowered Blood Pressure, Cholesterol and Weight Using Mobile Technology 2. Atlantic Health System’s Morristown Medical Center Treats First Patient in New Jersey with Edwards’ EVOQUE Tricuspid Valve Replacement 3. Shorten the Blanking Period After Atrial Fibrillation Ablation, Experts Say 4. Medtronic Launches the Avalus Ultra Valve Engineered for Ease of Use at Implant and Lifetime Patient Management 5. Incentives Prompt Increased Daily Walking in Patients at Risk for Heart Disease 6. Novel CT Exam Reduces Need for Invasive Artery Treatment 7. FDA Announces Recalls of Abbott/Thoratec Corp. Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) Due to Long-term Buildup of biological material Causing an Obstruction 8. Around 10% of Deaths from Coronar
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
May 2, 2024 — Reprieve Cardiovascular, Inc. (‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart Failure. Heart failure (HF) is a leading cause of hospitalization in the United States. Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described. Nearly 20 years ago, the Acute Decompensated Heart Failure National Registry (ADHERE) was published[1] and described inpatient HF treatment patterns and decongestion outcomes in a prospective national database of HF hospitalizations across 275 community and academic medical centers. As a national community-based cohort, Trajectory and Response to Emergently Administered Therapy for Acute Heart Failure (TREAT-AHF) is a contemporary registry that characterizes a diverse population of 262,673 pa
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
@DAICeditor @RapidAI #AngioFlow by RapidAI will facilitate confident clinical decision-making immediately prior to or after #neuro_interventional procedures: https://t.co/XRpGMuIEHp #ArtificialIntelligence #FDA